I define genomics as the unbiased interrogation of the genome using high throughput technology. Sequencing one mutant locus using Sanger sequencing does not fall under this definition - I don't think IBM's business model is using Watson to interpret that. So when other people point out that HER2 is a useful genomic marker they are missing the point - HER2 can be determined with immunohistochemistry for example which has been around for 50 years.
I'm not sure what your question is... genomics has research value, for sure, it's great.
Is it worth trying to incorporate it into routine care? Yes, probably, if you have enough cash. Should a hospital pay for a black box machine learning algorithm to make recommendations from a highly polluted, often erroneous and hugely incomplete literature corpus? The alternative put forward by people actually doing the science is that we should try and develop large open source databases/repositories about the significance of genomic findings, and then collect the data about what happens to the patients.
I'm not sure what your question is... genomics has research value, for sure, it's great. Is it worth trying to incorporate it into routine care? Yes, probably, if you have enough cash. Should a hospital pay for a black box machine learning algorithm to make recommendations from a highly polluted, often erroneous and hugely incomplete literature corpus? The alternative put forward by people actually doing the science is that we should try and develop large open source databases/repositories about the significance of genomic findings, and then collect the data about what happens to the patients.